International Flavors & Fragrances (IFF) secured a new heart‑health claim for its isolated soy protein from Food Standards Australia New Zealand (FSANZ) on March 31 2026. The approval allows manufacturers in Australia and New Zealand to market soy protein as a component that helps maintain healthy blood cholesterol levels, a first for IFF in these markets.
The claim is supported by a daily intake of 20‑25 grams of isolated soy protein as part of a balanced diet, and it aligns with FSANZ’s broader framework that recognizes soy protein’s role in cardiovascular health. The regulatory decision opens a new pathway for IFF’s soy protein portfolio, giving the company a science‑backed marketing lever in two large consumer markets.
In the same week, IFF reported its Q4 2025 results. Net sales fell 7% to $2.59 billion, but the company beat revenue estimates of $2.52 billion. Adjusted earnings per share were $0.80, missing consensus of $0.85 by $0.05. The miss was largely due to a 4% decline in comparable currency‑neutral sales in the Food Ingredients segment, offset by a 2% gain in the Taste segment. Adjusted operating EBITDA margin rose to 16.9% from 15.9% a year earlier, driven by higher pricing power in the Health & Biosciences line and disciplined cost management.
CEO Erik Fyrwald said the company delivered a solid 2025 performance, meeting its financial commitments despite a challenging operating environment. He highlighted portfolio optimization and a focus on higher‑value businesses as key drivers of the year‑end results, underscoring confidence in the company’s strategic direction.
The new heart‑health claim fits into IFF’s broader strategy to expand its Health & Biosciences segment. By gaining regulatory acceptance in Australia and New Zealand, IFF can differentiate its soy protein from competitors and support premium pricing. The approval also signals that IFF’s product quality and safety standards meet international expectations, potentially accelerating adoption in plant‑based food and beverage categories such as dairy alternatives, nutrition bars, and plant‑based proteins.
No immediate market reaction to the claim approval was reported, but the regulatory milestone is expected to enhance IFF’s competitive positioning and could drive incremental demand for its soy protein ingredients in the region.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.